Redeye comments on Annexin’s Q4 report and recent events and see good initial progress in the phase II study.
Redeye comments on Annexin’s Q3 report and recent events.
Redeye comments on Annexin Pharmaceuticals’ approval to start the phase IIa study in diabetic retinopathy (DR) and retinal vein occlusion (R...
Redeye comments on Annexin’s Q2 report and recent events in the company.
Redeye comments on Annexin's Q1 report and recent events in the company.
Redeye comments on today’s news that Annexin’s rights issue was fully subscribed.
Redeye comments on Annexin's Q3 report and recent events in the company, most notably the top-line data presented in August.
Redeye raises its base case following the positive readout in the phase IIa RVO study with ANXV.
Redeye gives an initial take on the positive phase IIa results in RVO with ANXV, an imporant milestone for the company.
Redeye comments on Annexin's Q2 report and recent events in the company.
Redeye comments on the positive outcome of Annexin’s rights issue.
Redeye endorses the latest progress with the ANXV phase II study in RVO and give our initial comment.
Redeye returns with an update following Annexin’s Q1 report, which offered no surprises.
Redeye comments on the news that Annexin has announced a rights issue of up to SEK45m.
Redeye returns with an update following Annexin’s Q4 report, and the company continued to present advancements from its ongoing phase II stu...
Redeye endorses yesterday's promising effect signal in 6 out of 8 patients followed for at least 3 months or longer in the ongoing phase II ...
Redeye comments on Annexin’s rights issue's outcome and adjusts our valuation.
Redeye briefly comments on Annexin Pharmaceuticals rights issue.
Redeye returns with an update following Annexin’s Q3 report.
Redeye endorses today’s news that Annexin has reported preclinical progress with its approach to use ANXV as a drug conjugate, ie to deliver...
Redeye comments on today’s news that Annexin has seen initial signals of effect in the ongoing phase II RVO study and also made some modific...
Redeye returns with an update following Annexin’s Q2 report.
Redeye reviews the case of Annexin in the wake of the company’s Q1 report and recent newsflow.
Redeye is encouraged by the first report from Annexin’s imaging study (n=16), which indicates site-specific accumulation of ANXV in vessels ...
Annexin Pharmaceuticals' CEO, Anders Haegerstrand, Chief Scientific and Medical Officer, Anna Frostegård, and Head of Therapeutic Area Oncol...
Tomorrow between 13:00-15:00, Annexin Pharmaceuticals' CEO, Anders Haegerstrand, Chief Scientific and Medical Officer, Anna Frostegård, and ...
Redeye comments on Annexin’s Q4 report, which came in as expected, and largely reiterate our view of the company.
Redeye gives a short comment on today’s news of a directed issue in Annexin, where the proceeds will be used to initiate a focus within canc...
Redeye comments on Annexin’s Q3 report, which came in as expected, and largely reiterate our view of the company.
Redeye comments on today’s Q2 report from Annexin Pharmaceuticals and largely reiterate our view of the company.
Yesterday evening, Annexin announced that it had decided on a directed share issue of SEK 10.
Redeye comments on yesterday’s Q1 report from Annexin Pharmaceuticals, which came in as expected.
Redeye comments on yesterday’s announcement regarding the outcome of Annexin’s TO3 warrant program.
Redeye is encouraged by today’s news that Annexin’s phase II trial is approved to start in the US as well as by the overall positive momentu...
We give a short comment on the news that Annexin Pharmaceuticals has in-licensed a patent related to the use of Annexin A5 in cancer.
Annexin Pharmaceuticals held a Strategy Update on the 30th of March.
Annexin Pharmaceuticals announced yesterday positive results from its anticipated phase I study, a milestone for the company and its lead ca...
Redeye maintains our view of Annexin Pharmaceuticals and Base case of SEK 4 following the company’s report for the second quarter.
